Dogwood Therapeutics (DWTX) EBT (2020 - 2026)

Dogwood Therapeutics has reported EBT for 7 years, with the latest figure at -$14.0 million in Q2 2026.

• On a quarterly basis, EBT fell 267.99% year-over-year to -$14.0 million in Q2 2026; TTM through Jun 2026 was -$38.5 million, a 56.78% decrease from a year earlier, with the FY2025 full-year figure at -$34.0 million, down 175.59% from the prior year.
• EBT was -$14.0 million for Q2 2026 at Dogwood Therapeutics, down from -$5.0 million in the prior quarter.
• The five-year high for EBT was -$1.0 million in Q2 2024, with the low at -$15.7 million in Q3 2025.
• Average EBT over 5 years is -$4.6 million, with a median of -$3.1 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: EBT soared 61.7% in 2023, then sank 731.26% in 2025.
• Over 5 years, EBT stood at -$2.0 million in 2022, then soared by 46.04% to -$1.1 million in 2023, then sank by 600.56% to -$7.7 million in 2024, then surged by 51.5% to -$3.7 million in 2025, then slumped by 273.75% to -$14.0 million in 2026.
• The last three EBT figures came in at -$14.0 million (Q2 2026), -$5.0 million (Q1 2026), and -$3.7 million (Q4 2025), per Business Quant data.